ContraFect (NASDAQ:CFRX) issued its earnings results on Thursday. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.17), Bloomberg Earnings reports.
ContraFect traded up $0.11, reaching $2.03, during mid-day trading on Friday, MarketBeat.com reports. The company’s stock had a trading volume of 126,100 shares, compared to its average volume of 171,774. ContraFect has a 12-month low of $0.80 and a 12-month high of $2.93. The firm has a market cap of $144.37 million, a price-to-earnings ratio of -5.49 and a beta of -0.51.
A number of equities analysts have weighed in on the company. Chardan Capital assumed coverage on ContraFect in a research report on Friday, June 15th. They issued a “buy” rating and a $2.80 target price for the company. Janney Montgomery Scott assumed coverage on ContraFect in a research report on Thursday, June 28th. They issued a “buy” rating for the company. ValuEngine raised ContraFect from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. Finally, LADENBURG THALM/SH SH assumed coverage on ContraFect in a research report on Tuesday, July 10th. They issued a “buy” rating for the company.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Featured Article: What is the Book Value of a Share?
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.